According to Supernus Pharmaceuticals 's latest financial reports the company's current earnings (TTM) are $5.18 M. a decrease over its 2022 earnings that were of $67.81 M.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 | $5.18 M | -92.36% |
2022 | $67.81 M | -29.8% |
2021 | $96.59 M | -49.79% |
2020 | $0.19 B | 12.99% |
2019 | $0.17 B | 7.58% |
2018 | $0.15 B | 54.9% |
2017 | $0.10 B | 84.25% |
2016 | $55.46 M | 202.27% |
2015 | $18.34 M | -462.04% |
2014 | -$5.07 M | -94% |
2013 | -$84.43 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $16.97 B | 327,291.98% | ๐บ๐ธ USA |
Abbott Laboratories ABT | $6.66 B | 128,449.38% | ๐บ๐ธ USA |
Eli Lilly LLY | $6.55 B | 126,339.04% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $8.44 B | 162,708.64% | ๐บ๐ธ USA |
Zogenix ZGNX | -$0.22 B | -4,190.10% | ๐บ๐ธ USA |
United Therapeutics UTHR | $1.33 B | 25,625.31% | ๐บ๐ธ USA |